6000 Shoreline Court
South San Francisco
254 articles with Veracyte, Inc.
The William Blair 39th Annual Growth Stock Conference in Chicago on Wednesday, June 5, 2019, at 2:00 p.m. CDT.
Veracyte Announces New Data Demonstrating Afirma Xpression Atlas’s Potential to Inform Treatment Selection for Patients with Medullary Thyroid Cancer to Be Presented at 2019 ASCO Annual Meeting
American Society of Clinical Oncology (ASCO) Annual Meeting being held May 31-June 4, 2019 in Chicago.
Veracyte Unveils Next-Generation Percepta Genomic Sequencing Classifier for Improved Lung Cancer Diagnosis
Researchers prospectively validated the Percepta GSC on 412 patients with lung nodules who had inconclusive results following bronchoscopy, a common nonsurgical procedure to diagnose lung cancer.
5/17/2019Biopharma companies add new leaders to executive roles and boards of directors.
Dr. Bhorade will lead medical affairs for Veracyte’s pulmonology products
Veracyte, Inc. announced that Bonnie H. Anderson, chairman and chief executive officer, is scheduled to present at the UBS Global Healthcare Conference in New York City on Monday, May 20, 2019 at 9:30 a.m. EDT.
Veracyte Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Veracyte, Inc. announced the closing of its public offering of 6,325,000 shares of common stock, including 825,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares, at a price to the public of $23.25 per share.
Veracyte, Inc. announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a public offering price of $23.25 per share.
Veracyte, Inc. announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock.
Veracyte, Inc. announced financial results for the first quarter ended March 31, 2019 and provided an update on recent business progress.
Dr. Bowie will lead the company’s strategic planning process and be responsible for identifying, evaluating and executing technology and business partnerships, licensing and acquisitions as well as managing biopharmaceutical collaborations to help drive long-term profitable growth for Veracyte.
Veracyte Receives Regulatory Authorization to Offer Envisia Genomic Classifier for Patients in New York State
Novel Genomic Test Helps Improve Diagnosis of Idiopathic Pulmonary Fibrosis
Veracyte Announces Publication Highlighting Afirma GSC’s Ability to Rule Out Cancer in Challenging Thyroid Nodule Subtype
RNA whole-transcriptome and machine learning platform enables genomic test to distinguish benign Hürthle cells, reducing potential for unnecessary surgeries
Veracyte Announces Data Published in The Lancet Respiratory Medicine Demonstrate that the Envisia Genomic Classifier Improves Diagnosis of IPF
Novel genomic test distinguishes IPF from other lung-scarring diseases without the need for surgery
A replay of the webcast will be available for 90 days following the conclusion of the live presentation broadcast.
Veracyte Announces New Afirma Xpression Atlas Data that Advance Genomic Understanding of Medullary Thyroid Cancer
Veracyte, Inc. (Nasdaq: VCYT) announced that new data from the Afirma® Xpression Atlas suggest that the majority of newly diagnosed medullary thyroid cancers (MTC) are associated with variants from three genes.
Veracyte, Inc. (Nasdaq: VCYT), a leading genomics diagnostics company, today announced its “Summit” level sponsorship of the Climb to Fight Cancer’s Team Kilimanjaro expedition as part of the company’s expanded efforts to combat this disease.
Veracyte Announces New Afirma Xpression Atlas Data on Medullary Thyroid Cancer to Be Presented at ENDO 2019
Veracyte, Inc. announced that new data derived from the Afirma® Xpression Atlas, which help characterize the genomic underpinning of medullary thyroid cancer, will be presented at ENDO 2019, the Endocrine Society’s annual meeting.
Genomic Test is the First to Be Granted Medicare Coverage for Improved Diagnosis of Idiopathic Pulmonary Fibrosis
Veracyte Announces Fourth Quarter and Full-Year 2018 Financial Results and Provides 2019 Financial Outlook
Veracyte, Inc. announced financial results and business progress for the quarter and full year ended December 31, 2018, and provided financial guidance for 2019.